SPRO compared with LYEL: revenue, margins and what each company keeps, and the suppliers and customers both name

SPROSpero Therapeutics, Inc.

Mkt capRevenueRevenue

LYELLyell Immunopharma, Inc.

Mkt capRevenueRevenue

Compare

SPROSpero Therapeutics, Inc.

LYELLyell Immunopharma, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

SPRO1 of 4 reports

0 of 1at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±64.1%▲+4.20%×0.07

LYEL2 of 4 reports

0 of 2at or beyond implied

Reportimpliedrealized× implied

Q3 FY26±28.5%▼−2.79%×0.10

Q2 FY26±35.4%▲+3.52%×0.10

= impliedSPRO realized, solidLYEL realized, hatchedOne scale, both sides: full bar = 65%× = |realized| ÷ impliedSource: market data

SPROSpero Therapeutics, Inc.

1.07▲+4.41%· post 1.04

Mkt cap$60.0MRevenue$258,000Q1 FY26Revenue$67MFY25

LYELLyell Immunopharma, Inc.

14.85▼−1.03%· post 14.85

ClosedNov 6 '26

Mkt cap$365.3MRevenue$3,000Q3 FY26Revenue$36,000FY25

Compare

ClosedNov 6 '26

SPROSpero Therapeutics, Inc.

LYELLyell Immunopharma, Inc.

1.07▲+4.41%post 1.04

Price

14.85▼−1.03%post 14.85

$60.0M

Mkt cap

$365.3M

Q1 FY26$258,000

Revenue

$3,000Q3 FY26

FY25$67M

Revenue

$36,000FY25

SPRO1.07▲+4.41%vsLYEL14.85▼−1.03%ClosedNov 6 '26